# A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis

> **NCT01292187** · PHASE2 · COMPLETED · sponsor: **Tarsa Therapeutics, Inc.** · enrollment: 129 (actual)

## Conditions studied

- Osteopenia

## Interventions

- **DRUG:** Oral calcitonin at dinnertime
- **DRUG:** Oral placebo at dinnertime
- **DRUG:** Oral calcitonin at bedtime
- **DRUG:** Oral placebo at bedtime

## Key facts

- **NCT ID:** NCT01292187
- **Lead sponsor:** Tarsa Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-05
- **Final completion:** 2012-07
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2014-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01292187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01292187, "A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01292187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*